Kailera Therapeutics Inc
KLRAHealthcare|Biotechnology|USA
$20.68
-0.33 (-1.57%)
Upcoming Data Readouts (4)
Jul 2027
Est. completion
P2Obesity
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
NCT07497880n=320
Feb 2028
Est. completion
P3Obesity
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875n=1,800
Mar 2028
Est. completion
P3Obesity
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979n=1,200
Mar 2028
Est. completion
P3Obesity With Diabetes
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901n=1,700